Last updated
BioNTech: Leadership Change
BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).
Source: HealthCare Middle East & Africa
- Who
- BioNTech · Biotech & Pharma · Germany
- What happened
- BioNTech's Chief Medical Officer Özlem Türeci is described as outgoing, per comments on the Q3 earnings call, as the company reviews its oncology pipeline (T-Pam, pumitamig, gotistobart).
- When
- 2026-11-13
- So what
- A change at the top rarely stays at the top.
The leadership read
A change at the top rarely stays at the top. BioNTech's move reshapes the layer beneath it in Biotech & Pharma as a new leader sets priorities and the team re-forms. Watch the first two or three appointments that follow; they signal direction more reliably than any statement.
Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; EMEA hiring signal is running rising (+5pts).
BioNTech: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 30 tracked companies.
MitchelLake in this thematic
More signals across Biotech & Pharma
Leadership Change · EMEA
Harbour BioMed →Harbour BioMed (HKEX: 02142) appointed Vivian Feng as Head of External Collaboration, a new senior role overseeing partnerships with external parties.
Leadership Change · EMEA
BioMarin Pharmaceutical Inc. →Ian T. Clark elected as new Chair of the Board, replacing retiring Richard A. Meier
Capital Raising · EMEA
Neobe Therapeutics →UK biotech Neobe Therapeutics raised $6.8M (£5M) in seed funding led by ARC Ventures, with participation from Faber, Macmillan Ventures, Proven Connect and Empirical Ventures, to advance its NEO22 engineered-bacteria cancer program toward an IND filing in 2028.
Capital Raising · EMEA
mbiomics →mbiomics secured a further €12M, bringing its Series A to €30M to advance microbiome-based therapeutics (as reported in a roundup of European biotech financings).
Geographic Expansion · EMEA
Bio-Techne →Bio-Techne is expanding its GMP manufacturing network with a new facility in Bristol, UK, to scale cell therapy development capabilities alongside existing North American operations.
Product Launch · EMEA
AviadoBio →AviadoBio has presented Phase 1/2 trial data for AVB-101, its investigational gene therapy for frontotemporal dementia with GRN mutations (FTD-GRN), showing dose-dependent increases in cerebrospinal fluid progranulin levels across four ascending doses.
Where this lands in our work
- Board Search & Advisory →
Incoming executives reshape governance needs within two quarters.
- Executive Search: EMEA →
Our EMEA practice runs the searches behind signals like this one.
Intelligence powered by Autonodal ↗
Nearby in the record
